Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03844230
Other study ID # 19294
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 24, 2019
Est. completion date December 31, 2022

Study information

Verified date April 2021
Source University of Illinois at Urbana-Champaign
Contact Marta Y Pepino, PhD
Phone (217) 300-2374
Email ypepino@illinois.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Data from several studies show that consuming a diet high in low-calorie sweeteners (LCS), mainly in diet sodas, is linked to the same metabolic disorders as consuming a diet high in added sugars, including an increased risk of developing type 2 diabetes. Sweet taste receptors, once thought to be unique to the mouth, have now been discovered in other parts of the body, including the intestine and the pancreas, where they play a role in blood sugar control. These newly identified receptors provide new avenues to explore how LCS may affect metabolism and health. This project is designed to examine the role of sweet taste signaling, both in the mouth and in the gut, on blood sugar control and how habitual consumption of LCS may affect sweet taste signaling and metabolism in people with obesity.


Description:

The overall goal of this research is to assess the role of oral and gut sweetness signaling in postprandial glucose metabolism and to determine how acute and chronic low-calorie sweetener (LCS) consumption may affect this signaling in people with obesity. The aims will determine the independent and combined contributions of pharmacological inhibition (Aim 1) or extra stimulation (Aim 2) of sweet taste signaling in the gut, mouth, or both on hormonal responses to an oral glucose tolerance test (OGTT) in two groups of subjects with obesity: habitual and non-habitual LCS consumers. Validated sensory evaluation techniques will also ascertain subjects' taste perception (Aim 3) to test the hypotheses that habitual consumption of LCS blunts perception of sweetness and, in turn, affects postprandial glucose regulation.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 31, 2022
Est. primary completion date November 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 40 Years
Eligibility Inclusion Criteria: - All races/ethnicities - Habitual (> 5 diet sodas per week) and non-habitual (=1 diet soda or 1 packet of LCS per week) LCS consumers - 30 = BMI <40 kg/m2 - Not severely insulin resistant (HOMA-IR2 < 2.6) Exclusion Criteria: - BMI < 30 and 40< BMI kg/m2 - HOMA-IR2>2.6 - Irregular LCS consumers (>1 diet sodas or packets of LCS per week but <5) - Current smokers or quit smoking nicotine cigarettes for less than 6 months ago - Pregnant, breastfeeding, menopausal - Presence of anemia : <12g/dl for women and <13g/dl for men - Blood donation in the past 8 weeks - Presence of malabsorption syndrome - History of bariatric surgery - Presence of inflammatory intestinal disease, liver or kidney disease - Have diabetes (fasting glucose level >126mg/dl or plasma glucose level 2h after glucose challenge >200 mg/dl) - Taking any medication that might affect glucose metabolism or the results of our study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Control - Inhibition
Taste and spit up water 10 minutes before drinking a glucose load
Experimental I- Inhibition
Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
Experimental II- Inhibition
Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
Control- Stimulation
Taste and spit up water 10 minutes before drinking a glucose load
Experimental I- Stimulation
Taste and spit up sucralose 10 minutes before drinking a glucose load
Experimental II- Stimulation
Drink sucralose 10 minutes before drinking a glucose load
Sensory Evaluation
Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold

Locations

Country Name City State
United States University of Illinois at Urbana Champaign Champaign Illinois

Sponsors (2)

Lead Sponsor Collaborator
University of Illinois at Urbana-Champaign Washington University School of Medicine

Country where clinical trial is conducted

United States, 

References & Publications (6)

Adams TB, Cohen SM, Doull J, Feron VJ, Goodman JI, Marnett LJ, Munro IC, Portoghese PS, Smith RL, Waddell WJ, Wagner BM; Expert Panel of the Flavor and Extract Manufacturers Association. The FEMA GRAS assessment of phenethyl alcohol, aldehyde, acid, and related acetals and esters used as flavor ingredients. Food Chem Toxicol. 2005 Aug;43(8):1179-206. Epub 2005 Jan 26. Review. — View Citation

Jiang P, Cui M, Zhao B, Liu Z, Snyder LA, Benard LM, Osman R, Margolskee RF, Max M. Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J Biol Chem. 2005 Apr 15;280(15):15238-46. Epub 2005 Jan 24. — View Citation

Karimian Azari E, Smith KR, Yi F, Osborne TF, Bizzotto R, Mari A, Pratley RE, Kyriazis GA. Inhibition of sweet chemosensory receptors alters insulin responses during glucose ingestion in healthy adults: a randomized crossover interventional study. Am J Clin Nutr. 2017 Apr;105(4):1001-1009. doi: 10.3945/ajcn.116.146001. Epub 2017 Mar 1. — View Citation

Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes Care. 2013 Sep;36(9):2530-5. doi: 10.2337/dc12-2221. Epub 2013 Apr 30. — View Citation

Schiffman SS, Booth BJ, Sattely-Miller EA, Graham BG, Gibes KM. Selective inhibition of sweetness by the sodium salt of +/-2-(4-methoxyphenoxy)propanoic acid. Chem Senses. 1999 Aug;24(4):439-47. — View Citation

Steinert RE, Gerspach AC, Gutmann H, Asarian L, Drewe J, Beglinger C. The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clin Nutr. 2011 Aug;30(4):524-32. doi: 10.1016/j.clnu.2011.01.007. Epub 2011 Feb 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma Glucose Blood samples will be collected before and for 5 hours after drinking a glucose load to determine plasma glucose concentration Up to 5 hours after drinking a glucose load
Primary Plasma Insulin Blood samples will be collected before and for 5 hours after drinking a glucose load to determine plasma insulin concentration Up to 5 hours after drinking a glucose load
Primary Plasma C-Peptide Blood samples will be collected before and for 5 hours after drinking a glucose load to determine plasma C-peptide concentration Up to 5 hours after drinking a glucose load
Primary Sensory Evaluation Participants will be tasting solutions containing different concentrations of glucose, sucrose and sucralose (some of the solutions will also have lactisole) to assess their detection threshold, sweet taste intensity and preference. They will have to rate the intensity of the solution on a general Labeled Magnitude Scale (gLMS) ranging from "no sensation" (0) to "strongest imaginable sensation" (100) and choose the solutions they prefer. Up to 2 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2